ClinicalTrials.gg
Enrolling by invitationNCT06549400Updated Jan 26, 2026

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.

A Phase 3 interventional study of Mexiletine granules for prolonged-release oral suspension in Myotonic Dystrophy, sponsored by Lupin Ltd.. Enrolling by invitation at 6 sites in 6 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Lupin Ltd. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
176
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Myotonic Dystrophy with a site in Belgium — 8 open to participants now, 9 under way, 4 of them phase 3. Myotonic Dystrophy · Belgium.

Planned enrollment
3rd of 10
176 · median 114
Started
2025
with 2 others
Phase 3
4 of 10
4 open now
Registered
6th of 10
by date
Lead sponsor
2 of 10
Lupin Ltd.

Among the 10 studies in Myotonic Dystrophy with a site in Belgium, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2025, is one of 4 in phase 3, and was the 6th registered.

Myotonic Dystrophy

127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

8 of the 10 studies in Myotonic Dystrophy with a site in Belgium are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Myotonic Dystrophy with a site in Belgium, or all of them as a file.
02

Study summary

This is an open-label extension study intended to evaluate the long-term safety and efficacy of mexiletine PR in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2) who have completed the parent study MEX-DM-302.

Read the detailed description

At the completion of the final visit in Study MEX-DM-302 patients who continued to meet the eligibility criteria will be invited to rollover into this open-label study for an additional 18 months. All patients who elect to continue into this open-label study will receive active mexiletine (no placebo).

Mexiletine PR will be started as 167 mg once a day (QD) treatment regimen. The dose will be titrated up at Week 1 to 333 mg and at Week 2 to a maximum dose of 500 mg QD depending on tolerability. If unable to tolerate the escalated dose, the dose will be reduced by one dose step during the titration period of the study to a maximum tolerated dose. Study drug should be taken with food at approximately the same time of the day every day, preferably in the morning (See Section 7 for further details on reconstitution and dosing titration).

Safety assessments include patient- and physician-reported adverse events, standard clinical laboratory evaluations, physical examinations, and vital signs. In addition, ECG, Holter monitors, and echocardiogram assessments will be collected to assess cardiac safety during the study.

03

Conditions studied

  • Myotonic Dystrophy

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. DM1 or DM2 diagnosis confirmed genetically;
  2. Ability to comprehend and willingness to sign an (ICF) or ICF of the parent(s)/legal guardian and written assent from the patient (if patient \< 18 years of age);
  3. Ability to understand the study requirements including intention to stay in the study until the end-of-study visit at 26 weeks of treatment;
  4. Male or non-pregnant female ≥16 years of age;
  5. (BMI) of 18.5 kg/m2 to 30 kg/m2, and weight ≥45 kg;
  6. Female patients of must be using a highly effective form of for the duration of the study and for at least 7 days after last dose of study drug;
  7. No significant cardiac abnormalities as determined by a cardiologist's assessment;
  8. Have sufficient finger flexor strength to grasp the handle of the dynamometer used to measure myotonia;
  9. DM1 patients only - Muscular impairment rating scale (MIRS) score of 2, 3 or 4.

Exclusion criteria

Exclusion Criteria:

  1. Are pregnant or lactating;
  2. Have any one of the following medical conditions: uncontrolled diabetes mellitus, cancer other than skin cancer less than five years previously (e.g., basal-cell carcinoma (BCC) and squamous-cell carcinoma (SCC) of skin allowed), multiple sclerosis, seizure disorders, or other serious medical illness;
  3. Severe renal impairment ( (GFR) \< 30 mL/min);
  4. Medical conditions which could interfere with muscle function such as infections, trauma, fractures, or planned surgery;
  5. Medical conditions that could affect hand functioning including but not limited to rheumatoid arthritis, Dupuytren's contracture, hand deformity, etc.;
  6. Severe arthritis or medical condition (other thanDM1/DM2) that would significantly impact ambulation;
  7. High incidence of falls or fall-associated fractures (>5 falls during the past 12 months);
  8. Preexisting elevated liver function tests > 3 times the (ULN) on Day 1 ( (ALT)/aspartate transaminase (AST), gamma-glutamyl transferase (GGT)) and/or any abnormal chemistry, hematology or urine lab considered by investigator;
  9. Serum potassium values \< 3.5 mmol/L or > 5.0 mmol/L or serum magnesium values \< 1.7 mg/dL. Electrolytic imbalance such as hypokalaemia, hyperkalaemia or hypomagnesaemia may increase the proarrhythmic effects of mexiletine. Electrolyte imbalances need to be corrected before administering mexiletine and will be monitored throughout treatment.
  10. Intake of any anti-myotonic treatment within 4 weeks prior to baseline (Day 1) or 5 half-lives, whichever is longer such as metformin, such as propafenone, flecainide, lamotrigine, carbamazepine or any other channel-blocker/ anticonvulsive drugs;
  11. Use of any concomitant medications that could increase the cardiac risk;
  12. Known allergy to mexiletine or any local anesthetics;
  13. Participation in another interventional clinical study during the last 3 months or 5 half-lives of the medicinal product, whichever is longer (with the exception of participation in the previous MEX-DM-302 study);
  14. Wheelchair-bound or bed-ridden;
  15. Any cardiac safety associated condition including any of the following criteria detected by cardiac evaluations including 24-hr Holter monitor, echocardiogram and clinical evaluations:

    • PR interval ≥240 ms or QRS duration ≥120 ms on resting
    • Personal history of 3rd degree or 2nd degree type 2 atrioventricular block or sinus node dysfunction with pauses ≥3 seconds, complete bundle branch block, bifascicular and trifascicular block or any heart block susceptible to evolve to complete heart block
    • Personal history of sustained atrial fibrillation, flutter or tachycardia (duration >30 seconds)
    • Personal history of non-sustained (ventricular triplets or more) or sustained ventricular tachycardia
    • Myocardial infarction (acute or past) or coronary artery stenosis >50%, presence of abnormal Q waves
    • (NYHA) Class II to IV heart failure
    • Left ventricular systolic dysfunction with \<50%
    • Sinus node dysfunction (including ECG sinus rate \<50 beats per minute (BPM))
    • Co-administration of antiarrhythmics inducing torsades de pointes (class Ia: quinidine, procainamide, disopyramide, ajmaline; class Ic: encainide, flecainide, propafenone, moricizine; class III: amiodarone, sotalol, ibutilide, dofetilide, dronedarone, vernakalant)
    • Co-administration of other classes of antiarrhythmics (class Ib: lidocaine, phenytoin, tocainide; class II: propranolol, esmolol, timolol, metoprolol, atenolol, carvedilol, bisoprolol, nebivolol; class IV: verapamil, diltiazem)
    • Patients with implantable cardioverter defibrillators (ICDs) and pacemakers are excluded
    • Presence of symptomatic coronary artery disease
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
176 participants (estimated)

Study arms

  • Other
    Mexiletine prolonged-release (PR)

    Mexiletine PR 167 mg (mexiletine HCl 200 mg) Mexiletine PR 333 mg (mexiletine HCl 400 mg) OR Mexiletine PR 500 mg (mexiletine HCl 600 mg)

    Drug: Mexiletine granules for prolonged-release oral suspension

Interventions

  • DrugMexiletine granules for prolonged-release oral suspension

    Mexiletine PR

06

What researchers measure

Primary outcomes

  1. To assess the long-term efficacy of once daily mexiletine PR for the symptomatic treatment of myotonia in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2) who have completed MEX-DM-302 study.

    Handgrip relaxation time in DM1 patients by mean change in baseline of handgrip relaxation time (seconds) after maximal voluntary isometric contraction (MVIC)

    Time frame: 78 weeks

Secondary outcomes

  1. To assess the long-term safety of once daily mexiletine PR for the symptomatic treatment of myotonia in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2) who have completed the MEX-DM-302 study

    Number and frequency of AEs/SAEs throughout the study while on treatment

    Time frame: 78 weeks

  2. Mean change in VAS

    Score for muscle stiffness (myotonia severity) as self-reported by patients on a Visual Analog Scale (VAS)

    Time frame: 78 weeks

  3. Mean change in MBS scores

    Mean change in Myotonia Behavior Scale (MBS) scores on a scale of 0 (no stiffness) to 5 (incapacitating stiffness)

    Time frame: 78 weeks

  4. Mean change in health-related quality of life

    Mean change in health-related quality of life (measured by INQoL)

    Time frame: 78 weeks

  5. Mean change in DM1-Activ-c scale (DM1 patients only)

    Mean change in measure of activity and social participation (measured by a Rasch-built scale with a 0-100 interval range)

    Time frame: 78 weeks

  6. Mean change in time to perform the 10-meter Walk Test

    Mean change in time (seconds) to perform the 10-meter Walk Test (10mWT)

    Time frame: 78 weeks

  7. Mean change in handgrip relaxation time

    Mean change in maximal voluntary isometric contraction (MVIC) and relaxation time by Video-recording of Hand Opening Time (VHOT) functional evaluation

    Time frame: 78 weeks

  8. Mean change in time to perform Timed-up and go (TUG) test

    Mean change in time (seconds) to perform Timed-up and go (TUG) test

    Time frame: 78 weeks

  9. Mean change in health-related quality of life measured by EQ-5D

    Mean change in health-related quality of life measured by EQ-5D (5-point scale)

    Time frame: 78 weeks

  10. Mean change in Myotonic Dystrophy Health Index (MDHI) score (DM1 patients)

    Mean change in Myotonic Dystrophy Health Index (MDHI) score (DM1 patients) as measured by patient's perceived health

    Time frame: 78 weeks

  11. Mean change in Myotonic Dystrophy 2 Health Index (MD2HI) score (DM2 patients)

    Mean change in Myotonic Dystrophy 2 Health Index (MDHI) score (DM2 patients) as measured by patient's perceived health

    Time frame: 78 weeks

  12. Assess the long-term safety of mexiletine PR by changes in ECG

    Mean change in ECG (PR, QRS, and QTc intervals in units of milliseconds \[ms\]) from baseline

    Time frame: 78 weeks

  13. Assess the long-term safety of mexiletine PR by changes in ECG (HR)

    Mean change in ECG (HR in units of beats per minute) from baseline

    Time frame: 78 weeks

  14. Assess the long-term safety of mexiletine PR by AEs

    Incidence of treatment emergent adverse events (TEAEs), treatment-related TEAEs, serious AEs, and patient discontinuation rate

    Time frame: 78 weeks

  15. Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (hematology measured in units of μL [microliters]) from change in baseline

    Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations as measured by hematology parameters in units of μL: white blood cell (WBC) with differential (absolute count), red blood cells (RBC), platelet count, and red blood cell indicies.

    Time frame: 78 weeks

  16. Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (hematology measured in units of % [percentage]) from change in baseline

    Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations as measured by hematology parameters in units of %: white blood cell (WBC) and differential (percentage) and hematocrit.

    Time frame: 78 weeks

  17. Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (hematology measured in g/dL [units of grams per deciliter]) from change in baseline

    Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations as measured by hematology parameters in units of g/dL: hemoglobin.

    Time frame: 78 weeks

  18. Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (chemistry measured in units of mmol/L) from change in baseline

    Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations as measured by chemistry parameters in units of mmol/L: chloride, carbon dioxide, potassium, and sodium

    Time frame: 78 weeks

  19. Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (chemistry measured in units of U/L) from change in baseline

    Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations as measured by chemistry parameters in units of U/L: alkaline phosphatase, aspartate aminotransferase (AST), aspartate transaminase (ALT), gamma-glutamyl transferase (GGT), and creatine phosphokinase.

    Time frame: 78 weeks

  20. Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (chemistry measured in units of g/dL) from change in baseline

    Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations as measured by chemistry parameters in units of g/dL: albumin and total protein.

    Time frame: 78 weeks

  21. Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (chemistry measured in units of mg/dL) from change in baseline

    Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations as measured by chemistry parameters in units of mg/dL: blood urea nitrogen (BUN), calcium, creatinine (eGFR), glucose, total bilirubin, and magnesium.

    Time frame: 78 weeks

  22. Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (urinalysis) from change in baseline

    Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations as measured by urinalysis parameters (measured as normal or abnormal): appearance, specific gravity, pH, protein, glucose, ketones, blood, leukocyte esterase, nitrite, bilirubin, urobilinogen, and microscopic examination.

    Time frame: 78 weeks

  23. Assess the long-term safety of mexiletine PR by vital signs (pulse)

    Assess the long-term safety of mexiletine PR by vital signs (pulse in units of bpm \[beats per minute\]) from change in baseline

    Time frame: 78 weeks

  24. Assess the long-term safety of mexiletine PR by vital signs (body temperature)

    Assess the long-term safety of mexiletine PR by vital signs (body temperature in units of Fahrenheit or Celsius) from change in baseline

    Time frame: 78 weeks

  25. Assess the long-term safety of mexiletine PR by vital signs (blood pressure)

    Assess the long-term safety of mexiletine PR by vital signs (blood pressure \[diastolic and systolic\] in units of mmHg \[millimeters of mercury\]) from change in baseline

    Time frame: 78 weeks

  26. Assess the long-term safety of mexiletine PR by vital signs (respiration)

    Assess the long-term safety of mexiletine PR by vital signs (respiration in units of breaths per minute) from change in baseline

    Time frame: 78 weeks

  27. Assess the long-term safety of mexiletine PR by physical examinations

    Assess the long-term safety of mexiletine PR by change in baseline from physical examinations (normal or abnormal) in the following regions and systems: general appearance, head and neck, heart, lung, abdomen, chest and back, upper extremities, lower extremities, neurological, and dermatological.

    Time frame: 78 weeks

07

Study locations

6 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for May 2028, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2024
First posted
Aug 12, 2024
StartActual
Sep 12, 2025
Primary completionEst.
May 29, 2028
CompletionEst.
Jul 6, 2028
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06549400
Lead sponsor
Lupin Ltd.
Collaborators
Lupin Atlantis Holdings S.A.
Responsible party
Sponsor
First posted
Aug 12, 2024
Start date
Sep 12, 2025
Primary completion
May 29, 2028 (estimated)
Completion
Jul 6, 2028 (estimated)
Last update
Jan 26, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion